OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Halmos on Recent Advancements in Non–Small Cell Lung Cancer

June 23rd 2020

Balazs Halmos, MD, MS, discusses recent advancements made in non–small cell lung cancer.

Dr. Richardson on First-In-Human Phase 1 Trial With CC-92480 in R/R Myeloma

June 23rd 2020

Paul G. Richardson, MD, discusses the patient population analyzed in the first-in-human phase 1 trial of the CELMoD CC-92480.

Dr. Furman on FDA-Approved BTK Inhibitors in B-Cell Malignancies

June 23rd 2020

Richard R. Furman, MD, discusses FDA-approved BTK inhibitors in B-cell malignancies.

Dr. Goldberg on Financial Toxicities Faced in Hematology

June 23rd 2020

Stuart L. Goldberg, MD, discusses financial toxicities faced in hematology.

Dr. Alistar on the Need to Develop Biomarkers in Pancreatic Cancer

June 22nd 2020

Angela Tatiana Alistar, MD, discusses the need to develop biomarkers in pancreatic cancer.

Dr. Sokolova on Implementing a Germline Testing Protocol for Metastatic Prostate Cancer

June 22nd 2020

Alexandra Sokolova, MD, discusses the systematic implementation of a germline testing protocol for patients with metastatic prostate cancer.

Dr. Hill on the FDA Approval of Selinexor in DLBCL

June 22nd 2020

Brian T. Hill, MD, PhD, discusses the FDA approval of selinexor (Xpovio) in diffuse large B-cell lymphoma (DLBCL).

Dr. Wang on Comparative Analysis of KTE-X19 in Higher- Versus Lower-Risk R/R MCL

June 22nd 2020

Michael Wang, MD, discusses the objectives of a comparative analysis of the phase 2 ZUMA-2 trial with KTE-X19 in patients with mantle cell lymphoma.

Dr. Ramakrishnan on the Promise of Biosimilars in Hematology

June 22nd 2020

Praveen Ramakrishnan, MD, discusses the promise of biosimilars in hematology.

Dr. Shore on the Rationale for the Phase 3 HERO Trial in Advanced Prostate Cancer

June 22nd 2020

Neal D. Shore, MD, FACS, discusses the rationale for conducting the phase 3 HERO trial in advanced prostate cancer.

Dr. Huey on Challenges Faced With Immunotherapy in HCC

June 20th 2020

Ryan W. Huey, MD, discusses challenges faced with immunotherapy in hepatocellular carcinoma.

Dr. Wolf on the Design of GEOMETRY mono-1 Trial in METex14-Mutated NSCLC

June 20th 2020

Jüergen Wolf, MD, discusses the design and rationale of the phase 2 GEOMETRY mono-1 study with capmatinib (Tabrecta) in METex14-mutated or high MET amplified, advanced non–small cell lung cancer.

Dr. Wang on the Safety and Efficacy of KTE-X19 in R/R MCL

June 20th 2020

Michael Wang, MD, discusses the safety and efficacy of KTE-X19 in relapsed/refractory mantle cell lymphoma.

Dr. Talati on the Rationale for Venetoclax in AML

June 19th 2020

Chetasi Talati, MD, discusses the rationale for investigating venetoclax in acute myeloid leukemia.

Dr. Sokolova on the Rationale for Systematic Implementation of Germline Testing for Metastatic Prostate Cancer

June 19th 2020

Alexandra Sokolova, MD, discusses the rationale for systematic implementation of germline testing for patients with metastatic prostate cancer.

Dr. Dimopoulos on the Utility of Zanubrutinib in Waldenström Macroglobulinemia

June 19th 2020

Meletios A. Dimopoulos, MD, discusses the utility of zanubrutinib (Brukinsa) in Waldenström macroglobulinemia.

Dr. Morris on Deciding Among PET Tracers in Prostate Cancer

June 19th 2020

Michael J. Morris, MD, discusses factors to consider when deciding among PET tracers in prostate cancer.

Dr. Kelly on Identifying Optimal Dose of Radium-223 and Niraparib in mCRPC

June 19th 2020

William K. Kelly, DO, discusses the design of a phase 1B dose-finding trial that evaluated the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.

Dr. Kuruvilla on the Treatment Landscape in Relapsed/Refractory Hodgkin Lymphoma

June 19th 2020

John Kuruvilla, MD, FRCPC, discusses the treatment landscape in relapsed/refractory Hodgkin lymphoma.

Dr. Sands on the FDA Approval of Lurbinectedin in Small Cell Lung Cancer

June 19th 2020

Jacob Sands, MD, discusses the FDA approval of lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer with disease progression, following platinum-based chemotherapy.